NAFLD in normal weight individuals
Abstract Nonalcoholic fatty liver disease (NAFLD) can develop in lean individuals. Despite a better metabolic profile, the risk of disease progression to hepatic inflammation, fibrosis, and decompensated cirrhosis in the lean is similar to that in obesity-related NAFLD and lean individuals may exper...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-03-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13098-022-00814-z |
| _version_ | 1818356629613051904 |
|---|---|
| author | Johanna K. DiStefano Glenn S. Gerhard |
| author_facet | Johanna K. DiStefano Glenn S. Gerhard |
| author_sort | Johanna K. DiStefano |
| collection | DOAJ |
| description | Abstract Nonalcoholic fatty liver disease (NAFLD) can develop in lean individuals. Despite a better metabolic profile, the risk of disease progression to hepatic inflammation, fibrosis, and decompensated cirrhosis in the lean is similar to that in obesity-related NAFLD and lean individuals may experience more severe hepatic consequences and higher mortality relative to those with a higher body mass index (BMI). In the absence of early symptoms and abnormal laboratory findings, lean individuals are not likely to be screened for NAFLD or related comorbidities; however, given the progressive nature of the disease and the increased risk of morbidity and mortality, a clearer understanding of the natural history of NAFLD in lean individuals, as well as efforts to raise awareness of the potential health risks of NAFLD in lean individuals, are warranted. In this review, we summarize available data on NAFLD prevalence, clinical characteristics, outcomes, and mortality in lean individuals and discuss factors that may contribute to the development of NAFLD in this population, including links between dietary and genetic factors, menopausal status, and ethnicity. We also highlight the need for greater representation of lean individuals in NAFLD-related clinical trials, as well as more studies to better characterize lean NAFLD, develop improved screening algorithms, and determine specific treatment strategies based on underlying etiology. |
| first_indexed | 2024-12-13T20:00:15Z |
| format | Article |
| id | doaj.art-298405b90c774194b9b852cd429490bb |
| institution | Directory Open Access Journal |
| issn | 1758-5996 |
| language | English |
| last_indexed | 2024-12-13T20:00:15Z |
| publishDate | 2022-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Diabetology & Metabolic Syndrome |
| spelling | doaj.art-298405b90c774194b9b852cd429490bb2022-12-21T23:33:12ZengBMCDiabetology & Metabolic Syndrome1758-59962022-03-0114111810.1186/s13098-022-00814-zNAFLD in normal weight individualsJohanna K. DiStefano0Glenn S. Gerhard1Diabetes and Fibrotic Disease Research Unit, Translational Genomics Research InstituteLewis Katz School of Medicine, Temple University School of MedicineAbstract Nonalcoholic fatty liver disease (NAFLD) can develop in lean individuals. Despite a better metabolic profile, the risk of disease progression to hepatic inflammation, fibrosis, and decompensated cirrhosis in the lean is similar to that in obesity-related NAFLD and lean individuals may experience more severe hepatic consequences and higher mortality relative to those with a higher body mass index (BMI). In the absence of early symptoms and abnormal laboratory findings, lean individuals are not likely to be screened for NAFLD or related comorbidities; however, given the progressive nature of the disease and the increased risk of morbidity and mortality, a clearer understanding of the natural history of NAFLD in lean individuals, as well as efforts to raise awareness of the potential health risks of NAFLD in lean individuals, are warranted. In this review, we summarize available data on NAFLD prevalence, clinical characteristics, outcomes, and mortality in lean individuals and discuss factors that may contribute to the development of NAFLD in this population, including links between dietary and genetic factors, menopausal status, and ethnicity. We also highlight the need for greater representation of lean individuals in NAFLD-related clinical trials, as well as more studies to better characterize lean NAFLD, develop improved screening algorithms, and determine specific treatment strategies based on underlying etiology.https://doi.org/10.1186/s13098-022-00814-zNAFLDNASHLeanNonobeseBMIPrevalence |
| spellingShingle | Johanna K. DiStefano Glenn S. Gerhard NAFLD in normal weight individuals Diabetology & Metabolic Syndrome NAFLD NASH Lean Nonobese BMI Prevalence |
| title | NAFLD in normal weight individuals |
| title_full | NAFLD in normal weight individuals |
| title_fullStr | NAFLD in normal weight individuals |
| title_full_unstemmed | NAFLD in normal weight individuals |
| title_short | NAFLD in normal weight individuals |
| title_sort | nafld in normal weight individuals |
| topic | NAFLD NASH Lean Nonobese BMI Prevalence |
| url | https://doi.org/10.1186/s13098-022-00814-z |
| work_keys_str_mv | AT johannakdistefano nafldinnormalweightindividuals AT glennsgerhard nafldinnormalweightindividuals |